VijayPD Ceutical FY26 net profit rises 7.4% to ₹505.75 lakh
VijayPD Ceutical Limited announced its audited financial results for FY26, reporting a 7.4% rise in net profit to ₹505.75 lakh. Revenue stood at ₹9,895.64 lakh. The company adjusted ₹418.24 lakh of IPO expenses against its Securities Premium Account and has ₹855.75 lakh of IPO proceeds pending utilization. The Board also re-appointed M/s. Sodha & Associates as Internal Auditor for FY27.
*this image is generated using AI for illustrative purposes only.
VijayPD Ceutical Limited reported a net profit of ₹505.75 lakh for the financial year ended March 31, 2026, reflecting a 7.4% increase compared to ₹471.03 lakh in the previous year. Revenue from operations for FY26 stood at ₹9,895.64 lakh, slightly lower than the ₹10,023.40 lakh recorded in FY25. The company’s Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 30, 2026.
The statutory auditors, M/s. J. D. Shah Associates, issued an audit report with an unmodified opinion on the financial results. However, the auditors drew attention to an aggregate expenditure of ₹418.24 lakhs incurred in connection with the company's Initial Public Offering (IPO). This amount, which includes certain costs in excess of the issue-related expenses disclosed in the Draft Prospectus, was adjusted against the Securities Premium Account in accordance with the Companies Act, 2013.
Financial Performance
For the year ended March 31, 2026, the company reported a total income of ₹10,298.74 lakh, up from ₹10,098.72 lakh in the prior year. Total expenses increased to ₹9,645.19 lakh from ₹9,458.91 lakh in FY25. The company’s earnings per share (EPS) for the year stood at ₹3.03 on a basic and diluted basis, compared to ₹3.77 in the previous year.
| Particulars | Year ended March 31, 2026 (₹ in Lakhs) | Year ended March 31, 2025 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 9,895.64 | 10,023.40 |
| Total Income | 10,298.74 | 10,098.72 |
| Total Expenses | 9,645.19 | 9,458.91 |
| Profit for the Period | 505.75 | 471.03 |
| Earnings Per Share (Basic) | 3.03 | 3.77 |
IPO Proceeds and Utilization
The company successfully completed its IPO, raising proceeds of ₹1,925.00 lakh. As of March 31, 2026, the company had utilized ₹1,069.25 lakh of the total proceeds. The utilization included ₹227.08 lakh for funding capital expenditure, ₹510.00 lakh for the repayment of borrowings, ₹74.17 lakh for general corporate purposes, and ₹258.00 lakh for issue-related expenses. The remaining ₹855.75 lakh is pending utilization and is held in fixed deposits and current accounts.
Corporate Developments
During the year, the company entered into a Share Purchase Agreement to acquire a 100% stake in M/s Siddarth Drugs Private Limited on April 7, 2026. Additionally, the Board re-appointed M/s. Sodha & Associates, Chartered Accountants, as the Internal Auditor for the financial year 2026-27. The consolidated financial results for FY26 include the financials of subsidiary M/s Zen Pharmaceutical from December 1, 2025.
Historical Stock Returns for Vijaypd Ceutical
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.77% | -4.32% | -15.31% | +97.82% | +152.65% | +152.65% |
How will the acquisition of M/s Siddarth Drugs Private Limited impact the company's revenue and market share in the upcoming fiscal year?
What specific capital expenditure projects will the remaining ₹855.75 lakh in IPO proceeds fund, and what is the expected timeline for deployment?
Will the inclusion of M/s Zen Pharmaceutical's financials from December 2025 drive consolidated profitability growth in FY27?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
